Workflow
Bringspring tech.(300290)
icon
Search documents
荣科科技(300290) - 2018年1月30日投资者关系活动记录表
2022-12-04 10:24
投资者关系活动记录表 证券代码:300290 证券简称:荣科科技 荣科科技股份有限公司投资者关系活动记录表 编号:2018-002 | --- | --- | --- | |----------------|-----------------------------|------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | | □其他 (请文字说明其他活动内容) | | 参与单位名称及 | | | | 人员姓名 | 信达证券股份有限公司 袁海宇 | | | 时间 | 2018 年 1 月 30 | 日 14:30 | | 地点 | 公司会议室 | | | 上市公司接待人 | | | | 员姓名 | | 董事会秘书张羽、证券事务代表徐蓉蓉 | 1 投资者关系活动记录表 | --- | --- | |----------------|--------------------------- ...
荣科科技(300290) - 2018年1月29日投资者关系活动记录表
2022-12-04 10:22
投资者关系活动记录表 证券代码:300290 证券简称:荣科科技 荣科科技股份有限公司投资者关系活动记录表 编号:2018-001 | --- | --- | --- | |----------------|-----------------------------|------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | | □其他 (请文字说明其他活动内容) | | 参与单位名称及 | | | | 人员姓名 | 东北证券股份有限公司 何柄谕 | | | 时间 | 2018 年 1 月 29 | 日 15:00 | | 地点 | 公司会议室 | | | 上市公司接待人 | | | | 员姓名 | | 董事会秘书张羽、证券事务代表徐蓉蓉 | 1 投资者关系活动记录表 | --- | --- | |----------------|--------------------------- ...
荣科科技(300290) - 2022 Q2 - 季度财报
2022-08-29 16:00
Acquisitions and Business Expansion - The company has completed acquisitions of Shanghai Mijian, Beijing Shenzhou Shihan, and Shanghai Jinchuang, enhancing its position in the medical information technology sector[4] - The company plans to deepen its business lines and expand product offerings to smooth out seasonal revenue fluctuations, which are primarily concentrated in the fourth quarter[6] - The company continues to focus on the smart healthcare and health data sectors, leveraging a dual-wheel drive model of "subsidiary + platform" for market expansion[39] - The company is investing heavily in technology innovation and exploring new service models to improve user engagement and brand value[4] - The company is transitioning to a cloud value-added service provider, offering comprehensive solutions that include online and offline support for various industries[45] Financial Performance - The company's operating revenue for the reporting period was ¥302,731,206.63, a decrease of 21.80% compared to the same period last year[32] - Net profit attributable to shareholders was ¥20,952,618.38, representing a significant increase of 72.34% year-on-year[32] - The net profit after deducting non-recurring gains and losses was -¥30,959,402.04, a decline of 428.51% compared to the previous year[32] - The net cash flow from operating activities improved by 25.23%, amounting to -¥121,594,663.18[32] - The total assets at the end of the reporting period were ¥1,717,124,147.86, down 8.40% from the end of the previous year[32] Risks and Challenges - The company has identified risks related to goodwill impairment from acquisitions, emphasizing the need for strong management of subsidiaries to mitigate this risk[10] - The company faces risks from intensified market competition and must innovate to maintain its competitive edge[4] - The company is committed to improving its talent retention strategies to combat the risk of losing high-quality personnel in a competitive market[7] Strategic Partnerships and Market Position - The company aims to strengthen strategic partnerships with domestic platform vendors to enhance market competitiveness amid global economic challenges[14] - The company plans to deepen cooperation with large industrial groups and strengthen R&D investment to maintain its competitive edge in the Northeast region[47] - The company aims to establish communication channels with national ministries and actively participate in national-level research associations to enhance its brand image[47] Innovation and Product Development - The smart hospital solution integrates products from subsidiaries, emphasizing a data-driven approach and utilizing big data, AI, and blockchain technologies[40] - The digital health city initiative aims to enhance healthcare services through a digital upgrade, focusing on user needs and establishing a digital health brain[43] - The company has added 39 new software copyrights during the reporting period, reflecting its commitment to innovation and product development[50] - The company is focused on enhancing the functionality and architecture of its cloud platform, exploring new industry solutions based on IoT and data middle platforms[45] Financial Management and Investments - The company reported a fair value change loss of ¥88,006,343.75 during the reporting period, with total fair value assets amounting to ¥123,887,972.92[69] - The company has no financial liabilities reported, indicating a strong balance sheet position[64] - The total investment amount for the reporting period was ¥2,029,814.92, a significant decrease of 97.57% compared to ¥83,616,622.94 in the same period last year[66] - The company has committed to returning bank loans totaling 1,217.50 million, fully realized[77] Shareholder and Governance Matters - The company will not distribute cash dividends or issue bonus shares for the reporting period[15] - The company held a temporary shareholders' meeting on April 1, 2022, with an investor participation rate of 21.51%[85] - The company held its annual shareholders' meeting on June 2, 2022, with an investor participation rate of 20.23%[85] - The company has committed to not engaging in any related party transactions that could harm its interests or those of its shareholders[100] Social Responsibility and Community Engagement - The company has been recognized as a key enterprise for epidemic prevention and control by the Liaoning Provincial Department of Industry and Information Technology, reflecting its significant role in public health during the pandemic[94] - The company has strengthened its commitment to social responsibility, particularly in the fields of smart cities and healthcare, addressing community needs and enhancing public welfare[89] - The company has created job opportunities and enhanced employee engagement during the pandemic, providing training and support to employees facing operational challenges[95] Compliance and Regulatory Matters - The company has committed to compensating for any losses incurred due to violations of its commitments[100] - The company has implemented a stock incentive plan with a lock-up period of 12, 24, and 36 months for the granted restricted stocks[105] - The company has taken measures to ensure compliance with internal controls regarding guarantee responsibilities[106] Financial Reporting and Accounting Practices - The financial statements are prepared based on the enterprise accounting standards, ensuring a true and complete reflection of the company's financial status[175] - The company has established policies for handling transaction costs related to mergers, recognizing them as expenses in the period incurred[180] - The company recognizes expected credit losses based on the risk of default weighted by the average expected loss over the life of the financial instrument[199]
荣科科技(300290) - 2022 Q1 - 季度财报
2022-04-28 16:00
Financial Performance - The company's revenue for Q1 2022 was ¥117,915,538.19, a decrease of 16.95% compared to ¥141,983,062.98 in the same period last year[3] - The net profit attributable to shareholders was a loss of ¥23,275,506.84, representing a decline of 1,074.94% from a profit of ¥2,387,374.05 in Q1 2021[3] - Basic and diluted earnings per share were both -¥0.0365, a decrease of 1,012.50% from ¥0.0040 in Q1 2021[3] - Net profit for Q1 2022 was a loss of ¥20,730,010.84, compared to a profit of ¥4,403,859.62 in Q1 2021, indicating a significant decline in profitability[23] - Total operating revenue for Q1 2022 was ¥117,915,538.19, a decrease of 16.9% compared to ¥141,983,062.98 in Q1 2021[21] - Total operating costs for Q1 2022 were ¥138,720,594.82, down 5.5% from ¥146,744,917.97 in the previous year[21] Cash Flow - The net cash flow from operating activities was negative at ¥158,765,752.43, which is a 5.78% increase in cash outflow compared to ¥150,097,216.16 in the previous year[3] - Cash flow from operating activities was ¥132,148,083.00 in Q1 2022, down from ¥147,783,146.83 in Q1 2021, reflecting a decrease of 10.6%[24] - Total cash inflow from operating activities was $140,136,790.44, while total cash outflow was $298,902,542.87, resulting in a significant cash outflow[25] - The net cash flow from investing activities was -$11,068,448.56, a decrease from -$46,025,424.92 year-over-year, showing an improvement of approximately 76.0%[26] - Cash inflow from financing activities totaled $7,192,264.18, while cash outflow was $45,456,386.37, leading to a net cash flow from financing activities of -$38,264,122.19[26] Assets and Liabilities - Total assets at the end of Q1 2022 were ¥1,740,536,945.88, down 7.15% from ¥1,874,629,684.36 at the end of the previous year[3] - Total liabilities decreased to ¥677,447,274.54 in Q1 2022 from ¥790,960,002.18 in Q1 2021, a reduction of 14.3%[20] - The company’s total equity decreased to ¥1,063,089,671.34 in Q1 2022 from ¥1,083,669,682.18 in Q1 2021, a decline of 1.9%[20] - Total current assets decreased from 1,233,191,095.06 CNY to 1,096,044,783.21 CNY, a reduction of about 11.1%[18] Shareholder Information - Total number of common shareholders at the end of the reporting period was 23,672[12] - The largest shareholder, Henan Xinchuan Shuchuang Private Equity Investment Fund, holds 20.02% of shares, totaling 128,000,000 shares[12] Expenses - Sales expenses increased by 33.10% to ¥22,055,075.77 compared to ¥16,569,728.24 in Q1 2021, primarily due to increased sales efforts and personnel investment[9] - Research and development expenses increased to ¥14,775,317.77 in Q1 2022, up from ¥12,658,512.52 in Q1 2021, indicating a focus on innovation[21] Investment Performance - Investment income showed a significant loss of ¥945,862.11, a decline of 1,511.91% compared to a profit of ¥66,991.60 in the previous year[9] - Cash inflow from investment activities decreased by 97.73% to ¥794,832.20 from ¥35,071,047.55 in Q1 2021[10] Management Changes - The company announced the resignation of its chairman and another board member due to work changes and personal reasons[15] - The board of directors proposed new candidates for non-independent directors, which were approved at the shareholders' meeting[15] Other Information - The company did not conduct an audit for the first quarter report[27] - The report was released by the board of directors on April 28, 2022[28]
荣科科技(300290) - 2021 Q4 - 年度财报
2022-04-28 16:00
Financial Performance - The company reported a significant loss for the year, with specific reasons and measures for improving profitability detailed in the management discussion section[6]. - The company's operating revenue for 2021 was RMB 817,309,721.17, representing a 3.73% increase compared to RMB 787,896,467.61 in 2020[25]. - The net profit attributable to shareholders for 2021 was a loss of RMB 404,820,551.48, a decrease of 603.71% from a profit of RMB 80,368,462.37 in 2020[25]. - The net cash flow from operating activities for 2021 was RMB 455,136.20, down 99.60% from RMB 113,833,220.60 in 2020[25]. - The total assets at the end of 2021 were RMB 1,874,629,684.36, a decrease of 5.46% from RMB 1,982,963,071.10 at the end of 2020[25]. - The net assets attributable to shareholders at the end of 2021 were RMB 1,037,189,051.24, down 24.06% from RMB 1,365,823,220.26 at the end of 2020[25]. - The basic earnings per share for 2021 was -RMB 0.6538, a decline of 566.00% from RMB 0.1403 in 2020[25]. - The diluted earnings per share for 2021 was also -RMB 0.6538, a decrease of 568.67% from RMB 0.1395 in 2020[25]. - The weighted average return on equity for 2021 was -33.44%, a drop of 40.02 percentage points from 6.58% in 2020[25]. - The company reported a significant decline in net profit, with a loss of RMB 368,944,269.35 after deducting non-recurring gains and losses in the fourth quarter[28]. Acquisitions and Business Strategy - The company completed acquisitions of 100% of MiJian Information and ShenZhou Vision, and 80% of Shanghai JinChuang, enhancing its position in the medical information technology sector[9]. - The company plans to integrate its business systems, organizational structure, and marketing networks post-acquisition to enhance profitability and core competitiveness[10]. - The company is pursuing a strategy of domestic substitution in technology, planning to strengthen its market position over the next three years[43]. - The company aims to leverage national policies and economic advantages to enhance its core business areas of smart healthcare and smart cities, targeting a leadership role in these sectors[111]. Market and Industry Trends - The aging population in China is projected to exceed 210 million by 2025, increasing the demand for healthcare services significantly[34]. - The COVID-19 pandemic has accelerated the demand for digital healthcare services, highlighting the need for online medical consultations[35]. - The company anticipates growth opportunities in the smart healthcare and cloud industry due to favorable government policies and economic stability[37]. - The smart healthcare market in China is projected to grow rapidly, with the industry size surpassing 100 billion yuan in recent years, driven by government support and digital economy advancements[111]. Risks and Challenges - The company faces risks related to market competition, emphasizing the need for technological and business model innovation to maintain competitiveness[7]. - The company acknowledges potential risks from global economic slowdowns and geopolitical tensions that could impact its operations and market conditions[10]. - The company is experiencing seasonal revenue fluctuations, with significant income typically realized in the fourth quarter due to client budgeting and procurement cycles[7]. Research and Development - The company reported a research and development investment of ¥99,128,147.31 in 2021, representing 12.13% of its operating revenue, an increase from 9.62% in 2020[78]. - The company is committed to advancing its technology through continuous research and development in healthcare and energy sectors[46]. - The company registered 95 new software copyrights during the reporting period, enhancing its intellectual property portfolio[45]. - The company has developed a comprehensive health data management system, which is expected to improve healthcare service delivery[45]. Governance and Management - The company appointed He Renhui as the new CEO and promoted Ling Xingang to Vice President following the board restructuring[130]. - The board of directors underwent a significant change with the resignation of four directors and the appointment of new members, including He Hangxiao and Hu Changgen[129]. - The company has implemented strict internal control systems to ensure independence from its controlling shareholder in various aspects[123]. - The company is focused on enhancing its governance framework to support its strategic objectives and market expansion[129]. Financial Obligations and Compliance - The company reported a significant increase in development expenditures to ¥18,527,080.94, which is 0.99% of total assets, attributed to increased R&D investments[89]. - The company is actively managing its financial obligations and ensuring compliance with regulatory requirements regarding guarantees and liabilities[192]. - The company reported a total of ¥25,582.97 million in guarantees, with ongoing communication regarding the resolution of these issues[192]. - The company has committed to ensuring that all transactions with related parties are conducted fairly and transparently, adhering to legal and regulatory requirements[184]. Employee and Talent Management - The company has established a long-term incentive mechanism to attract and retain talent, aligning the interests of shareholders and management[121]. - The total employee compensation for the year was CNY 207.47 million, with core technical personnel compensation totaling CNY 40.66 million, accounting for 19.60% of the total[158]. - The number of R&D personnel decreased by 13.60% from 353 in 2020 to 305 in 2021, with R&D personnel now accounting for 29.24% of the total workforce[77]. Future Outlook - The company has provided a revenue guidance of 1.8 billion RMB for the next fiscal year, which reflects an expected growth of 20%[144]. - New product launches are expected to contribute an additional 300 million RMB in revenue, with a focus on innovative technology solutions[143]. - The company plans to increase its marketing budget by 30% to boost brand awareness and customer engagement[144].
荣科科技(300290) - 关于参加2021年辽宁辖区上市公司投资者网上集体接待日活动的公告
2021-12-07 09:12
1 关于参加 2021 年辽宁辖区上市公司投资者网上集体接待日活动的公告 证券代码:300290 证券简称:荣科科技 公告编号:2021-116 荣科科技股份有限公司 关于参加2021年辽宁辖区上市公司投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流,荣科科技股份有限公司(以下简称"公司") 将参加"2021 年辽宁辖区上市公司投资者网上集体接待日"活动。 投资者可于 2021 年 12 月 10 日(周五)15:30 至 17:00,登陆全景网投资者关 系互动平台(https://ir.p5w.net/)参与本次活动。届时公司高管将通过网络在线 交流的形式,与投资者就公司治理、经营状况、发展战略、风险防控、投资者保护 等投资者关注的问题进行沟通。 欢迎广大投资者积极参与。 特此公告。 荣科科技股份有限公司董事会 二〇二一年十二月七日 ...
荣科科技(300290) - 2021 Q3 - 季度财报
2021-10-26 16:00
Revenue and Profit - Revenue for Q3 2021 reached ¥288,274,336.33, an increase of 44.48% compared to the same period last year[4] - Total operating revenue for Q3 2021 reached ¥675,407,500.85, an increase of 40.5% compared to ¥480,623,037.81 in the same period last year[24] - Net profit attributable to shareholders decreased by 48.01% to ¥4,348,551.57 in Q3 2021, while year-to-date net profit decreased by 9.07% to ¥16,506,511.11[4] - Net profit for Q3 2021 was ¥26,766,840.77, a decrease of 6.1% from ¥28,519,947.65 in Q3 2020[25] - Earnings per share (basic) for Q3 2021 was ¥0.0268, down from ¥0.0320 in the previous year[25] Cash Flow - The company reported a significant decline in cash flow from operating activities, with a net cash outflow of ¥186,314,480.88 year-to-date, representing a 210.08% decrease[4] - The cash inflow from operating activities totaled CNY 596,671,370.62, an increase from CNY 518,011,815.61 in the previous year, representing a growth of approximately 15.1%[28] - The net cash outflow from operating activities was CNY -186,314,480.88, compared to CNY -60,086,868.92 in the same period last year, indicating a decline in cash flow performance[28] - The cash inflow from investment activities was CNY 82,139,669.88, down from CNY 186,617,134.57, reflecting a decrease of about 56.0%[28] - The net cash outflow from investment activities was CNY -54,800,096.70, compared to CNY -150,619,489.50 in the previous year, showing an improvement in cash flow[28] - The cash inflow from financing activities amounted to CNY 269,831,477.16, an increase from CNY 215,218,221.86, representing a growth of approximately 25.4%[29] - The net cash flow from financing activities was CNY 94,181,025.93, compared to CNY 87,159,897.48 in the same period last year, indicating a slight increase[29] - The total cash and cash equivalents at the end of the period were CNY 235,251,326.03, up from CNY 158,424,921.19, reflecting a growth of approximately 48.4%[29] Assets and Liabilities - Total assets increased by 9.88% to ¥2,178,814,219.78 compared to the end of the previous year[4] - The company’s total liabilities as of September 30, 2021, were CNY 1,267,170,610.71, reflecting an increase from the previous year[21] - Total liabilities as of the end of Q3 2021 amounted to ¥605,023,455.44, compared to ¥572,277,727.23 at the end of Q3 2020, reflecting a growth of 5.7%[24] - The company’s total equity attributable to shareholders increased by 11.85% to ¥1,527,611,804.20 compared to the end of the previous year[4] - Total equity attributable to shareholders of the parent company increased to ¥1,527,611,804.20 from ¥1,365,823,220.26, representing an increase of 11.9%[24] Research and Development - The company’s R&D expenses rose by 49.43% to ¥18,906,152.58, reflecting increased investment in new product development[9] - Research and development expenses for Q3 2021 were ¥44,614,966.96, an increase of 16.0% from ¥38,398,142.23 in the same quarter last year[24] Inventory and Receivables - Accounts receivable increased by 32.81% to ¥689,680,475.16, driven by the expansion of business operations[8] - Accounts receivable increased significantly to CNY 689,680,475.16 from CNY 519,317,597.44, representing a growth of about 32.8% year-over-year[21] - Inventory levels rose to CNY 182,964,345.47, compared to CNY 126,107,583.51 at the end of 2020, indicating a growth of approximately 45%[22] - The company reported a significant increase in prepayments, which rose by 152.38% to ¥41,698,919.71, indicating higher procurement activity[8] Employee and Operational Costs - The company reported a significant increase in cash paid to employees, totaling CNY 175,996,677.54, compared to CNY 121,065,241.98 in the previous year, which is an increase of about 45.2%[28] - The cash paid for purchasing goods and services was CNY 441,297,295.23, up from CNY 326,787,612.03, indicating a rise of approximately 35.0%[28] - The company’s gross profit margin was impacted by a 48.64% increase in operating costs, totaling ¥456,587,784.10 year-to-date[10] - Operating costs for the same period were ¥654,487,695.58, up 40.5% from ¥465,955,830.22 year-over-year[24] Shareholder Information - The company plans to transfer 128,000,000 shares, representing 20.02% of total shares, to the Henan Information Industry Fund Management Co., Ltd.[18] - The number of restricted shares at the end of the period was 70,965,603, with 33,750 shares released during the quarter[17] Miscellaneous - The company did not undergo an audit for the third quarter report[30] - The cash flow from operating activities details were not provided in the available documents[26] - The company has not disclosed specific future outlook or guidance in the provided content[27]
荣科科技(300290) - 2021 Q2 - 季度财报
2021-08-26 16:00
Acquisitions and Market Position - The company has completed acquisitions of Shanghai Mijian, Beijing Shenzhou Shihan, and Shanghai Jinchuang, enhancing its position in the medical information technology sector[12]. - The company is facing intensified market competition and is investing in differentiated innovation to maintain a leading position in its niche market[6]. - The company is currently in the process of a potential change in control, pending formal agreements and regulatory approvals[15]. Financial Performance - The company's operating revenue for the reporting period reached RMB 387,133,164.52, representing a 37.72% increase compared to RMB 281,098,894.29 in the same period last year[34]. - The net profit attributable to shareholders of the listed company was RMB 12,157,959.54, up 24.20% from RMB 9,789,175.71 in the previous year[34]. - The net profit after deducting non-recurring gains and losses was RMB 9,424,291.46, reflecting a 28.37% increase from RMB 7,341,650.23 year-on-year[34]. - The company's total assets at the end of the reporting period amounted to RMB 2,071,680,626.28, a 4.47% increase from RMB 1,982,963,071.10 at the end of the previous year[34]. - The net assets attributable to shareholders of the listed company increased by 10.91% to RMB 1,514,785,467.71 from RMB 1,365,823,220.26 at the end of the previous year[34]. - The basic earnings per share for the reporting period was RMB 0.0201, an increase of 15.52% compared to RMB 0.0174 in the same period last year[34]. - The diluted earnings per share was RMB 0.0201, up 16.18% from RMB 0.0173 year-on-year[34]. - The net cash flow from operating activities was negative at RMB -162,635,075.48, a decline of 72.56% compared to RMB -94,245,872.85 in the previous year[34]. Revenue and Cost Management - The company plans to deepen its business lines and expand product offerings to smooth out seasonal revenue fluctuations, which are primarily concentrated in the fourth quarter[8]. - The company acknowledges risks related to seasonal revenue patterns, particularly in the first half of the year, and is implementing strategies to mitigate these risks[8]. - Operating costs increased to ¥247,161,831.04, up 33.49% from ¥185,156,407.01, primarily due to the expansion of business scale[54]. - The company reported a significant increase in sales expenses, which rose by 50.61% to ¥42,178,533.03, compared to ¥28,005,847.43 in the previous year[54]. Research and Development - Research and development expenses rose by 41.41% to ¥38,528,530.81, compared to ¥27,245,741.85 in the previous year, reflecting increased investment in R&D[54]. - The smart hospital solution focuses on a data-driven approach, integrating big data, AI, and blockchain to enhance hospital information systems and improve healthcare services[43]. - The company is committed to continuous innovation in cloud services, focusing on digital transformation and business innovation for its clients[46]. Strategic Partnerships and Talent Management - The company emphasizes the importance of talent retention amid increasing competition for skilled professionals in the industry[9]. - The company is enhancing its strategic partnerships with domestic platform vendors to promote localization efforts and improve service competitiveness[14]. Cash Flow and Investments - The net cash flow from financing activities improved significantly to ¥102,317,226.35, a 352.24% increase from -¥40,562,826.79, attributed to increased cash received from investments[55]. - The company reported a total of RMB 1,051.77 million in overdue receivables from wealth management products, with RMB 21.04 million in impairment provisions[86]. - The company has invested RMB 8,000.00 million in bank wealth management products during the reporting period[86]. Shareholder Returns and Equity - The company will not distribute cash dividends or issue bonus shares for the current period[17]. - The company has not reported any new patents during the reporting period[75]. - The company has not implemented any share buybacks during the reporting period[140]. Compliance and Governance - The company and its subsidiaries are not classified as key pollutant discharge units by the environmental protection department, and there were no penalties for violating environmental laws during the reporting period[104]. - There were no significant litigation or arbitration matters during the reporting period[114]. - The semi-annual financial report was not audited, which may affect the reliability of the financial data presented[157].
荣科科技(300290) - 2021 Q1 - 季度财报
2021-04-28 16:00
Financial Performance - The company's revenue for Q1 2021 was ¥141,983,062.98, representing a 46.42% increase compared to ¥96,971,018.34 in the same period last year[8] - Net profit attributable to shareholders was ¥2,387,374.05, a significant turnaround from a loss of ¥14,813,929.04 in the previous year, marking a 116.12% improvement[8] - The net profit after deducting non-recurring gains and losses was ¥1,736,732.61, compared to a loss of ¥15,380,780.62 last year, reflecting an increase of 111.29%[8] - Basic earnings per share improved to ¥0.0040 from a loss of ¥0.0264, indicating a 115.15% increase[8] - Operating profit for Q1 2021 was CNY 5,222,823.84, a significant recovery from a loss of CNY 14,790,014.87 in Q1 2020[49] - Net profit for Q1 2021 was CNY 4,403,859.62, compared to a net loss of CNY 14,115,406.58 in Q1 2020, marking a turnaround[49] - The total comprehensive income for the period was ¥4,403,859.62, compared to a loss of ¥13,946,784.87 in the previous year[50] Cash Flow - The net cash flow from operating activities was -¥150,097,216.16, a decline of 6.88% compared to -¥140,432,508.14 in the same period last year[8] - Cash flow from operating activities increased by 62.36% year-on-year, driven by higher cash receipts from sales of goods and services[20] - Cash flow from investment activities rose by 74.58% year-on-year, primarily due to increased cash receipts from investment recoveries[20] - Cash flow from financing activities surged by 319.47% year-on-year, mainly due to increased cash from borrowings[20] - The company generated cash inflows from operating activities totaling ¥159,926,988.40, compared to ¥98,501,552.24 in the previous period[54] - The company's cash and cash equivalents decreased to CNY 200,392,460.36 from CNY 383,850,263.97 at the end of 2020, representing a decline of approximately 47.8%[39] - The ending balance of cash and cash equivalents rose to $85,536,506.49 from $32,526,333.82, marking a significant increase of approximately 162.5%[59] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,931,927,715.88, a decrease of 2.57% from ¥1,982,963,071.10 at the end of the previous year[8] - The total liabilities decreased to CNY 516,421,859.39 from CNY 572,277,727.23, a decline of about 9.8%[41] - Total current assets decreased to CNY 479,263,387.03 as of March 31, 2021, from CNY 542,979,632.45 at the end of 2020, a decline of approximately 11.7%[43] - Current liabilities decreased to CNY 460,834,989.72 from CNY 516,620,333.46, reflecting a reduction of about 10.8%[41] - The company's long-term equity investments increased to CNY 2,694,419.11 from CNY 195,893.26, marking a substantial rise of approximately 1,276.5%[40] Shareholder Information - The company reported a total of 15,576 common shareholders at the end of the reporting period[12] - The largest shareholder, Liaoning Guoke Industrial Co., Ltd., held 22.85% of the shares, amounting to 136,529,042 shares, with 90,000,000 shares pledged[12] Acquisitions and Investments - The company completed acquisitions of 100% equity in MiJian Information and ShenZhou Vision, and 70% equity in JinChuang, which will enhance its asset scale and business scope[25] - The company has allocated CNY 28,000 million for the acquisition of ShenZhou Vision, with 100% of the funds utilized[30] - The total amount of raised funds is CNY 56,610 million, with CNY 16.37 million invested in the current quarter[30] - The cumulative amount of raised funds utilized is CNY 54,244.26 million, achieving a utilization rate of 100% for certain projects[30] Risks and Challenges - The company faces risks related to accounts receivable increase, which has grown alongside sales scale, necessitating enhanced management and collection efforts[24] - The company is actively managing the risk of goodwill impairment from acquisitions, ensuring stable operations of subsidiaries with significant goodwill[24] - The company emphasizes the importance of talent retention and enhancement of compensation and benefits to mitigate human resource risks[24] - The company is integrating its acquisitions to improve operational efficiency and achieve synergy effects, although there are risks if the integration does not meet expectations[25] Research and Development - Research and development expenses for Q1 2021 were CNY 12,658,512.52, up from CNY 7,637,843.23 in Q1 2020, indicating an increase of approximately 66.5%[49] - Research and development expenses increased to ¥2,791,541.58, up from ¥1,464,601.16, reflecting a focus on innovation[51] Regulatory and Compliance - The company has received approval from the China Securities Regulatory Commission for a specific stock issuance, currently processing the registration and listing of new shares[26] - The first quarter report was not audited, which may affect the reliability of the financial data presented[60]
荣科科技(300290) - 2020 Q4 - 年度财报
2021-04-23 16:00
Acquisitions and Strategic Partnerships - The company has completed acquisitions of 100% of MiJian Information and ShenZhou Vision, and 70% of Shanghai JinChuang, enhancing its position in the medical information technology sector[6]. - The company aims to strengthen strategic partnerships with domestic platform vendors to promote localization efforts and improve service competitiveness[9]. - The company has made strategic acquisitions to enhance its capabilities in the healthcare sector, including the acquisition of Shanghai Jinchuang Information Technology Co., Ltd.[110]. Financial Performance - The company's operating revenue for 2020 was RMB 787,896,467.61, representing an increase of 8.86% compared to RMB 723,766,459.30 in 2019[20]. - The net profit attributable to shareholders for 2020 was RMB 80,368,462.37, an increase of 86.24% from RMB 43,153,626.44 in 2019[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 72,050,661.62, up 74.20% from RMB 41,361,918.65 in 2019[20]. - The net cash flow from operating activities for 2020 was RMB 113,833,220.60, a 41.75% increase from RMB 80,302,890.18 in 2019[20]. - The total assets at the end of 2020 were RMB 1,982,963,071.10, reflecting a growth of 24.09% from RMB 1,597,976,549.12 at the end of 2019[20]. - The net assets attributable to shareholders at the end of 2020 were RMB 1,365,823,220.26, an increase of 25.33% from RMB 1,089,816,314.06 at the end of 2019[20]. - The basic earnings per share for 2020 was RMB 0.1403, representing a growth of 76.48% compared to RMB 0.0795 in 2019[20]. - The diluted earnings per share for 2020 was RMB 0.1395, an increase of 75.69% from RMB 0.0794 in 2019[20]. - The weighted average return on equity for 2020 was 6.58%, an increase of 2.42 percentage points from 4.16% in 2019[20]. - The company reported a net profit of RMB 62,214,643.82 in Q4 2020, significantly improving from previous quarters[22]. Revenue and Market Trends - The company achieved a main business revenue of 787.90 million yuan, representing a year-on-year growth of 8.86%[48]. - Revenue from the healthcare sector reached ¥436.53 million, accounting for 55.40% of total revenue, with a year-on-year growth of 15.49%[58]. - The company reported a 10% increase in overall revenue for the last fiscal year, reaching $200 million, driven by strong sales in its software solutions[40]. - The company is aware of the risks posed by global economic slowdowns and geopolitical tensions, which may impact IT demand and market competition[9]. - The smart healthcare market in China has achieved a CAGR of 18% over the past 7 years, with the market size reaching nearly 50 billion yuan in 2018[114]. - The projected market size for smart healthcare in China is expected to reach 59.5 billion yuan in 2020 and 79.2 billion yuan by 2023, indicating significant growth potential[114]. Research and Development - The company is investing heavily in R&D, with a budget allocation of $50 million for the development of new AI-driven healthcare analytics tools aimed at improving patient outcomes[42]. - The company has registered 131 new software copyrights during the reporting period, enhancing its intellectual property portfolio[39]. - The company has introduced a series of core business systems for smart cities, receiving positive feedback from the market and users[35]. - The company is actively leading innovation in smart healthcare, leveraging core technologies such as big data, cloud computing, and artificial intelligence[49]. - The company has established strategic development centers for cloud services and smart healthcare, accelerating the construction of new mechanisms and systems[49]. Operational Efficiency and Employee Management - The company is committed to improving employee retention through enhanced compensation and career development opportunities amid increasing competition for talent[6]. - The company has implemented a performance assessment system to enhance project management and customer satisfaction, resulting in improved project delivery efficiency[51]. - The company will focus on developing talent potential and establishing a learning organization to enhance overall employee quality and capabilities[129]. - The performance evaluation system will integrate market efforts, product innovation, and management innovation into year-end assessments, ensuring a multi-level incentive mechanism is effectively implemented[129]. Technology and Service Innovation - The company is actively exploring new service models to increase user engagement and brand value in response to evolving customer demands[4]. - The Smart Hospital solution integrates data-driven approaches with AI and blockchain technologies, aiming to enhance hospital information systems[30]. - The Zhihui Cloud platform is designed to support digital transformation across various industries, including finance, education, and healthcare, with a focus on cloud migration and management[32]. - The company is focusing on creating an open and collaborative ecosystem with IT partners to enhance service offerings and drive innovation[119]. - The company aims to enhance its cloud-based services, with a projected 30% increase in cloud service revenue driven by the growing demand for remote healthcare solutions[42]. Financial Management and Investments - The company has engaged in structured deposits with a range of interest rates from 3.20% to 3.70% across various time frames[176]. - The company has maintained a focus on low-risk financial products, ensuring capital preservation while seeking returns[176]. - The total amount of entrusted financial management reached 23,800.00 million, with no overdue amounts reported[176]. - The company has not reported any losses from its financial management activities, showcasing effective risk management practices[176]. - The company has successfully replaced pre-invested funds with raised funds amounting to CNY 9,072.20 million and CNY 2,073.95 million in two separate instances[104]. Shareholder and Equity Management - The company has implemented an equity incentive plan with a lock-up period of 12, 24, and 36 months for the granted restricted stocks[144]. - The company has established a profit compensation agreement for the acquisition projects, ensuring accountability for performance targets[146]. - The total number of ordinary shareholders at the end of the reporting period was 23,110, an increase from 15,576 at the end of the previous month[197]. - The company’s stock structure changed due to the lifting of restrictions on 41,697,950 shares, impacting the shareholding distribution[190]. - The company has committed to ensuring that no related party transactions will occur that could harm the interests of the company and its shareholders[141]. Compliance and Regulatory Commitments - The company will strictly adhere to the regulations set forth by the China Securities Regulatory Commission and other relevant authorities[141]. - The company has committed to not engaging in any competing business activities during the reporting period[144]. - The company has ensured that all commitments regarding avoiding competition and related party transactions have been fulfilled by the expiration date[143]. - The company guarantees compliance with relevant regulations and will not seek undue benefits through related party transactions[142].